Promising combo tackles relapsed lymphoma in small trial

NCT ID NCT02433795

Completed Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested a combination of two drugs, bendamustine and rituximab, in 27 people with relapsed or progressive marginal zone B-cell lymphoma. The goal was to see how well the treatment shrank or controlled the cancer. Participants had already tried at least one prior therapy. The study is complete, and results may help guide future treatment for this type of lymphoma.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bendamustine plus rituximab
What this could lead to: If successful, this combination could offer a treatment option for people with relapsed marginal zone lymphoma, helping to shrink or control the cancer.
What could go wrong: This is a small, phase 2 study with only 27 participants, so results may not apply to everyone. The treatment also has side effects like low blood counts and infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE B CELL LYMPHOMA

Contacts and locations

Locations

Chonbuk National University Hospital

Jeonju, Jeollabuk-do, 54907, South Korea
Chungnam National University

Daejeon, South Korea
Gachon University Gil Medical Center

Incheon, South Korea
Gyeongsang National University Hospital

Jinju, South Korea
Hallym University Medical Center

Anyang-si, South Korea
Inje Universit

Seoul, South Korea
Korea Cancer Center Hospital

Seoul, South Korea
Seoul National University Boramae Hospital

Seoul, South Korea
Seoul National University Bundang Hospital

Seongnam, South Korea
Seoul National University Hospital

Seoul, South Korea
The Catholic University of Korea

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.